Lakhoo Janesh, Perez Thomas H, Borgmann Anthony J, Brown Daniel B
Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee.
Semin Intervent Radiol. 2021 Oct;38(4):412-418. doi: 10.1055/s-0041-1733903. Epub 2021 Oct 7.
Historically, outcomes reporting for radioembolization with yttrium-90 ( Y) of hepatocellular carcinoma has included patients across the range of Barcelona Clinic Liver Cancer (BCLC) stages. With the potential for curative radiation segmentectomy for BCLC 0/A patients and evolution of systemic therapy for BCLC C patients, focused review by group is of increasing interest. In this review, we report on efficacy of Y in patients with intermediate (BCLC B) and advanced (BCLC C) hepatocellular carcinoma as well as expected toxicities. Additionally, we review existing trials comparing Y to transarterial chemoembolization and systemic treatments in these patient groups and outline future studies.
从历史上看，肝细胞癌钇-90（Y）放射性栓塞治疗的疗效报告涵盖了巴塞罗那临床肝癌（BCLC）各阶段的患者。鉴于BCLC 0/A期患者有进行根治性放射节段切除术的可能性，以及BCLC C期患者全身治疗的进展，按分组进行重点回顾越来越受到关注。在本综述中，我们报告了Y对中期（BCLC B）和晚期（BCLC C）肝细胞癌患者的疗效以及预期毒性。此外，我们回顾了在这些患者群体中将Y与经动脉化疗栓塞和全身治疗进行比较的现有试验，并概述了未来的研究。
